Aylin ALTAY KOÇAK, Gülendam BOZDAYI, Aysu DUYAN ÇAMURDAN, İdil YENİCESU, Şeniz GÖRAL

Parvovirus B19 seroprevalence in Turkish blood donors

Background/aim: Parvovirus risk in blood transfusion has become a popular research topic since there are limited data on parvovirusseroprevalence in blood donors in Turkey. The aim of this study was to investigate parvovirus seroprevalence in blood donors in Turkey.Materials and methods: Blood samples of 988 blood donors admitted to a university blood bank were obtained for parvovirus B19 IgMand IgG detection. The samples were analyzed using the ELISA method.Results: IgM positivity of 3.92% and IgG positivity of 58.9% was detected in the blood samples. Parvovirus IgM positivity was found tobe the highest in the age group of 41–50 years (P = 0.045) and IgG positivity was detected to be the highest in the age group of 31–40years (P < 0.001). Parvovirus IgG positivity was significantly higher in women (P = 0.041). However, there was no difference regardingparvovirus IgM positivity in terms of sex (P = 0.245).Conclusion: Although this study does not represent the whole country, it is still the largest investigation carried out on the topic inTurkey and the obtained results are generally similar to those of European countries. Therefore, it is thought that the results obtainedfrom this study may be supportive for the first steps regarding plasma fractionation, which will soon begin in Turkey.

PDF

___

Gallinella G. Parvovirus B19 achievements and challenges. ISRN Virol 2013; 2013: 898730.
Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. P Natl Acad Sci USA 2004; 101, 32: 11628-11633.
Mossong J, Hens N, Friederichs V, Davidkin I, Broman M, Litwinska B, Siennicka J, Trzcinska A, Van Damme P, Beutels P et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol Infect 2008; 136: 1059-1068.
Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53: 459-475.
Marano G, Vaglio S, Pupella S, Facco G, Calizzani G, Candura F, Liumbruno GM, Grazzini G. Human parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus 2015; 13: 184-196.
Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998; 26: 89-94.
Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204.
Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011; 51: 1887-1895.
Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R et al. Parvovirus B19 revised. Transfus Med Hemother 2010; 37: 339-350.
Goeyvaerts N, Hens N, Ogunjimi B, Aerts M, Shkedy Z, Van Damme P, Beutels P. Estimating infectious disease parameters from data on social contacts and serological status. J Royal Stat Soc 2010; 13: 255-277.
US Food and Drug Administration. Guidance for Industry: Nucleic Acid Testing (NAT) To Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products. Washington, DC, USA: FDA; 2009.
Council of Europe. Human Plasma (Pooled and Treated for Virus Inactivation), Monograph 1646. Strasbourg, France: Council of Europe; 2008.
Lefrere JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106: 2890-2895.
Türk Dağı H, Özdemir M, Baykan M, Baysal B. Investigation of parvovirus B19 seroprevalence in various age groups in Central Anatolia Region, Turkey. Mikrobiyol Bul 2010; 44: 467-472.
Motor VK, Arıca S, Motor S, Yılmaz N, Evirgen Ö, İnci M, Gökçe C, Önlen Y. Investigation of parvovirus B19 seroprevalence, endothelin-1 synthesis, and nitric oxide levels in the etiology of essential hypertension. Clin Exp Hypertens 2012; 34: 217-221.
Erden S, Keskin F, Çiftçi S, Çınar S, Deniz G. The relationship between parvovirus B19 and Hashimoto’s thyroiditis. Turkiye Klinikleri J Med Sci 2013; 33: 98-102.
Motor VK, Üstün N, Evirgen Ö, İnci M, Yula E, Önlen Y. The seropositivity of parvovirus B19 in patients with ankylosing spondylitis. Turk J Phys Med Rehab 2014; 60: 37-40.
Gaggero A, Rivera J, Colquin E, Larranaga CE, Leon O, Diaz P, Gaggero N. Seroprevalence of IgG antibodies against parvovirus B19 among blood donors from Santiago, Chile. Rev Med Chil 2007; 135: 443-448.
Siennicka J, Stefanoff P, Trzcinska A, Rosinska M, Litwinska B. Seroprevalence study of parvovirus B19 in Poland. Przeglad Epidemiol 2006; 60: 571-580.
Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect 2000; 124: 449-457.
Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25: 151-153.
Manaresi E, Gallinella G, Marselli Labate AM, Zucchelli P, Zaccarelli D, Ambretti S, Delbarba S, Zerbini M, Musiani M. Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors. Epidemiol Infect 2004; 132: 857-862.
Bhattarakasol P, Pancharoen C, Kowitdamrong E, Thammaborvorn R, Mungmee V. Prevalence of parvovirus B19 infection in Thai young adults. Southeast Asain J Trop Med Public Health 2003; 34: 585-588.
Ooi SL, Hooi PS, Chua BH, Lam SK, Chua KB. Seroprevalence of human parvovirus B19 infection in an urban population in Malaysia. Med J Malaysia 2002; 57: 97-103.
Munoz S, Alonso MA, Fernandez MJ, Munoz JL, GarciaRodriguez JA. Seroprevalence versus parvovirus B19 in blood donors. Enferm Infecc Microbiol Clin 1998; 16: 161-162.
Letaief M, Vanham G, Boukef K, Yacoub S, Muylle L, Mertens G. Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusion transmission. Transfus Sci 1997; 18: 523-530.
Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, Gürtler L. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 2013; 98: 1495-1498.
Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G, Menichetti E, Lechner S, Wessin D, Prokoph B, Allain JP et al. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007; 47: 1775-1782.
Grabarczyk P, Korzeniowska J, Liszewski G, Kalińska A, Sulkowska E, Krug-Janiak M, Kopacz A, Łetowska M, Brojer E. Parvovirus B19 DNA testing in Polish blood donors, 2004- 2010. Przegl Epidemiol 2012; 66: 7-12.
Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 (Suppl. 2): 107-109.